
1. Pharmacogenomics. 2016 Nov;17(17):1903-1911. doi: 10.2217/pgs-2016-0131. Epub
2016 Oct 21.

The effect of SNPs in CYP450 in chloroquine/primaquine Plasmodium vivax malaria
treatment.

Sortica VA(1), Lindenau JD(1), Cunha MG(2), Ohnishi MD(3), Ventura AMR(3),
Ribeiro-Dos-Santos ÂK(4), Santos SE(4), Guimarães LS(5), Hutz MH(1).

Author information: 
(1)Departamento de Genética, Universidade Federal do Rio Grande do Sul, Porto
Alegre, RS, Brazil.
(2)Laboratório de Microbiologia e Imunologia, Universidade Federal do Pará,
Belém, PA, Brazil.
(3)Programa de Ensaios Clínicos em Malária, Instituto Evandro Chagas, Sistema de 
Vigilância Sanitária, Ministério da Saúde, Ananindeua, PA, Brazil.
(4)Laboratório de Genética Humana e Médica, Universidade Federal do Pará, Belém, 
PA, Brazil.
(5)Unidade de Bioestatística, Grupo de Pesquisa e Pós Graduação, Hospital de
Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.

BACKGROUND: Chloroquine/primaquine is the current therapy to eliminate Plasmodium
vivax infection in the Amazon region.
AIMS: This study investigates CYP1A2, CYP2C8, CYP2C9, CYP3A4 and CYP3A5 genetic
polymorphisms influence on cloroquine/primaquine treatment.
PATIENTS & METHODS: Generalized estimating equations analyses were performed to
determine the genetic influence in parasitemia and/or gametocytemia clearance
over treatment time in 164 patients.
RESULTS: An effect of CYP2C8 low-activity alleles on treatment was observed (p = 
0.01). From baseline to first day of treatment, wild-type individuals achieved
greater reduction of gametocytes than low-activity allele carriers. CYP2C9 and
CYP3A5 genes showed a trend for gametocytemia and parasitemia clearance rates.
CONCLUSION: Future studies should be performed to access the extent of CYP2C8,
CYP2C9 and CYP3A5 gene polymorphisms influence on cloroquine/primaquine
treatment.

DOI: 10.2217/pgs-2016-0131 
PMCID: PMC7099632
PMID: 27767381 

